New to companyGood Evening, I initiated a large position (large for me) in CXR last week. The main reason I was interested in this stock is the insanely low forward price to earnings ratio, and the more I read the more I was intrigued. I was thinking about adding more shares (should have pulled the trigger this morning!), as even after the gap up today it still seems to be very cheap to me on a fundamental basis. I apologize if this has already been covered on this board, but does anyone know why this is trading so cheaply? I looked at previous discussions and while there is a lot of "colorful" back and forth, I was having difficulty finding much in terms of real info and don't feel like reading back through weeks of discussion. Is there any confirmed link betweem this company to Valeant aside from them both being domiciled in Canada and in the same sector? My read is that this company has been unfairly painted by broad negativity over Valeant and US pharma in an election year. I do underatand that they do more business internationally now, and have a very different profile of drugs (less dependent on price increases) than Valeant and others in the space. But I feel like maybe I am missing something here. Also, I have read concerns about debt, but looking at the structure and lack of concerning covenants, really do not see much of an issue given earning potential. I guess what I am asking is am I missing something here? My conservative calculations say this should be in a range of 50 - 60 USD, with significant room to the upside should they deliver even slightly less than their guided earnings. So again, I just want to hear a little about the potential issues, as I am not seeing much on here or from the analysts aside from vague mentions about debt load. Any polite responses welcome! (Bears or bulls) Regards, Roger